AstraZeneca´s CALQUENCE® (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukemia Trials
(World News Science)

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are evaluating acalabrutinib alone and in combination for the treatment of chronic lymphocytic leukemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at ......